Bacitracin: An inhibitor of the insulin degrading activity of glutathione-insulin transhydrogenase

https://doi.org/10.1016/0006-291X(81)90858-5Get rights and content

Abstract

The antibiotic bacitracin, a known inhibitor of insulin degradation by both isolated cells and subcellular organelles, inhibited the ability of purified glutathione-insulin transhydrogenase to split insulin into its constituent A and B chains. This inhibition was demonstrated by measuring the formation of insulin degradative products that were both soluble in 5% trichloroacetic acid and chromatographed as the separate chains of insulin on Sephadex G-50. At concentrations of 90 and 300 μM, bacitracin inhibited 50 and 90%, respectively, of the degrading activity of the purified enzyme. Similarly, degradation by crude liver lysates was inhibited 50 and 90% by 70 and 250 μM bacitracin, respectively. Kinetic studies indicated that this inhibition was by a complex mechanism that decreased both the Vmax and affinity of the enzyme for insulin. These data raise the possibility that the inhibition of glutathione-insulin transhydrogenase by bacitracin could account for part or all of the effects of this antibiotic on inhibition of insulin degradation by target cells.

References (31)

  • P. Freychet et al.

    J. Biol. Chem

    (1972)
  • S. Gammeltoft et al.

    Biochim. Biophys. Acta

    (1973)
  • S. Terris et al.

    J. Biol. Chem

    (1975)
  • R.D. Fussganger et al.

    J. Biol. Chem

    (1976)
  • J. Gliemann et al.

    J. Biol. Chem

    (1978)
  • K. Suzuki et al.

    J. Biol. Chem

    (1979)
  • O. Sonne et al.

    J. Biol. Chem

    (1980)
  • E.B. Knights et al.

    Lancet

    (1973)
  • B. Desbuquois et al.

    Biochim. Biophys. Acta

    (1974)
  • H.H. Tomizawa et al.

    J. Biol. Chem

    (1959)
  • F. Tietze

    Biochim. Biophys. Acta

    (1970)
  • W.C. Duckworth et al.

    Biochim. Biophys. Acta

    (1975)
  • P.T. Varandani et al.

    Arch. Biochem. Biophys

    (1977)
  • D.F. Carmichael et al.

    J. Biol. Chem

    (1977)
  • R.A. Roth et al.
  • Cited by (95)

    • Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis

      2014, Cellular Immunology
      Citation Excerpt :

      To date, little is known about the role of PDI in lower eukaryotes such as protozoan parasite, L. donovani and its relevance to host parasite interaction during visceral leishmaniasis. The precise mechanism, especially in relation to redox changes and its effects on immunological responses is also not completely understood [43,34,33,44]. The characterisation of PDIs obviously has important implication for the design of new drug or vaccine against Leishmania parasites.

    • Entamoeba histolytica: Biochemical characterization of a protein disulfide isomerase

      2011, Experimental Parasitology
      Citation Excerpt :

      Despite the slight difference between the Km values, the micromolar order and the highly similar enzymatic rate suggest that EhPDI acts mainly as oxidase/isomerase. The inhibitory effect of the antibiotic bacitracin, a well-known inhibitor of PDI enzymes (Roth, 1981; Mizunaga et al., 1990; Mandel et al., 1993), was evaluated on the oxidoreductase activities of recombinant EhPDI. Typical inhibition profiles were observed (Fig. 4) for the reductase, oxidase and isomerase activities, with apparent IC50 values of 1.137, 0.172 and 0.334 mM, respectively.

    • FAD oxidizes the ERO1-PDI electron transfer chain: The role of membrane integrity

      2005, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      FAD-driven oxidation was also hindered by bacitracin treatment. During these experiments, we found that bacitracin, the inhibitor of PDI oxidoreductase activity [34–36], completely inhibited the FAD-driven oxidation of ER lumenal proteins. These data suggest that FAD uses the Ero1-PDI pathway for the oxidation of ER proteins.

    View all citing articles on Scopus
    View full text